PIATA PRODUCTIEI DE MEDICAMENTE ROMANIA 2021

9.000 lei

SKU: 3df8233a1f8d Category:
CARACTERISTICI
  • Numar de pagini 43
  • Format .pdf
  • Perioada 2012-2020
  • Limba de redactare – Engleza
DESCRIERE STUDIU

This comprehensive research evaluates the Romanian pharmaceutical market. In order to understand the developments that took place on the Romanian market between 2012-2020 first chapter of the research analyzes the evolution of global market and its outlook.

The brief analysis of Romanian macroeconomic environment represents the starting point in evaluating and estimating the domestic pharmaceutical production market. Surveying major market’s players and analyzing public available data helped to determine the total value of the market. The market is described through its developments and features between 2012 and 2020; Top 10 most important players on the market, their financial data and indicators for a nine year period.

For deepening the research on Romanian market, an analysis on NACE codes is realized, based on values at national level (total companies that registered this activity as their core business). The companies were structured in 12 groups by turnover criterion: 0 EUR, 0-100 Th. EUR, 100-500 Th. EUR, 500 – 1,000 Th. EUR, 1-5 Mn. EUR, 5-10 Mn. EUR, 10-20 Mn. EUR, 20-50 Mn. EUR, 50-100 Mn. EUR, 100-500 Mn. EUR, 500-1000 Mn. EUR, and over 1000 Mn. EUR. It is a thorough review, where financial indicators such as turnover, net profit, total debt vs. total assets, total number of companies, number of companies with losses vs. companies with profit, number of employees, net profit margin are calculated and interpreted for 2012-2020.

In order to support companies on Romanian market and the ones planning to enter the market, a series of analyses were conducted (Porter Analysis, PEST Analysis and Value Chain Analysis), most important factors influencing market players’ activity were listed and recommendations for companies’ management were proposed.

Information and data on pharmaceutical market were obtained from a variety of sources: IMS Institute, IMAP, European Federation of Pharmaceutical Industries and Associations, National Institute of Statistics, National Commission for Prognosis, National Bank of Romania, the National Trade Register Office, Ministry of Finance, surveys of main players, national reports and analysis etc.

CONDITII DE LIVRARE
Se va livra în max 72 de ore de la confirmarea comenzii, timp necesar actualizării.
PREZENTARE REZUMATIVA
EXECUTIVE SUMMARY
I. GLOBAL PHARMACEUTICAL INDUSTRY (2012-2020)
1.1. Dynamic and structure of the pharmaceutical industry (2012-2020)
1.2. Pharmaceutical industry in global context (2012-2020)
1.3. Structure of the industry at the European Union level (2012-2020)
II. ROMANIAN PHARMACEUTICAL INDUSTRY (2012-2020)
2.1. Landmarks of the domestic macroeconomic context (2012-2020)
2.2. Analysis of the Romanian pharmaceutical industry (2012-2020)
2.3. Production dynamic in Romania (2012-2020)
2.4. Generic medicine (2012-2020)
III. MARKET ANALYSIS ON NACE CODES (2012-2020)
IV. ROMANIAN COMPETITIVE ENVIRONMENT ANALYSIS (2012-2020)
4.1. Competitive environment – top 10 companies (2012-2020)
4.2. Competitive environment – main competitors presentation (2012-2020)
V. MANAGEMENT CONSULTING ANALYSIS
5.1. Value chain analysis
5.2. Porter analysis
5.3. Pest analysis
5.4. Factors of influence
5.5. Managerial Recommendations
  1. Global spending on medicines 2012-2020
  2. Value of global transactions in the industry 2012-2020
  3. Structure of global investments-2020 (breakdown into regions)
  4. Global health spending 2012-2020
  5. Medicine production 2012-2020 at European level
  6. Imports and exports 2012-2020 at European level
  7. Expenditures on R&D in the industry 2012-2020 at European level
  8. GDP dynamic 2012-2020 – Romanian market
  9. Exchange rate dynamic 2012-2020 – Romanian market
  10. Healthcare budget vs. weight of healthcare expenditure in the GDP 2012-2020 – Romanian market
  11. Average consumption expenditures vs average expenditure for healthcare 2012-2020 – Romanian market
  12. Medicine sales 2012-2020 – Romanian market
  13. Medicine Sales – 2020 Q 1 (breackdown into types of diseases) – Romanian market
  14. Imports and exports 2012-2020 – Romanian market
  15. Market share -2020 Q1 (top 10 companies in the pharma industry) – Romanian market
  16. Medicine production 2012-2020 – Romanian market
  17. Expenditure for R&D in the industry 2012-2020– Romanian market
  18. Turnover evolution (breakdown on company size) 2012-2020 – Romanian market total NACE codes
  19. Market structure 2020 (breakdown on company size) – Romanian market total NACE codes
  20. Number of companies (breakdown on company size) 2012-2020 – Romanian market total NACE codes
  21. Turnover (2020 vs. 2019) vs. Number of firms variation (2020 vs. 2019) – Romanian market total NACE codes
  22. Number of employees (2020 vs. 2012) – Romanian market total NACE codes
  23. Average net profit margin (groups of companies on turnover criterion) 2012-2020 – Romanian market total NACE codes
  24. Average receivables turnover (groups of companies on turnover criterion) 2012-2020 – Romanian market total NACE codes
  25. Turnover / employee (groups of companies on turnover criterion) 2012-2020 – Romanian market total NACE codes
  26. Turnover / company (groups of companies on turnover criterion) 2012-2020 – Romanian market total NACE codes
  27. Average profitability 2012-2020 – Romanian market total NACE codes
  28. Turnover evolution (2020 vs. 2019) vs. Receivables turnover evolution (2020 vs. 2019) – Romanian market
  29. Turnover evolution (2020 vs. 2012) vs. Receivables turnover evolution (2020 vs. 2012) – Romanian market
  30. Weight of each company in total turnover of Top 10 players 2012-2020 – Romanian market
  31. Net profit margin of Top 10 players 2012-2020 – Romanian market
  32. Weight of each company in total number of employees of Top 10 players 2012-2020 – Romanian market
  33. Turnover / employee (Top 10 companies) 2012-2020 – Romanian market
  34. Net profit / employee (Top 10 companies) 2012-2020 – Romanian market
  35. Turnover / Employee and Net profit/ employee for each company included in Top 10 players (2012-2020)
  36. Each company’s weight in Top 10’ cumulated turnover 2012-2020 – Romanian market
  1. Total market (2020) – Romanian market
  2. The disappearance of generic medicine– Romanian market
  3. No. of profitable companies 2012 – 2020 – Romanian market total NACE codes
  4. No. of companies with loss 2012 – 2020 – Romanian market total NACE codes
  5. Net profit margin (groups of companies on turnover criterion) 2012 – 2020 – Romanian market total NACE codes
  6. Receivables turnover (groups of companies on turnover criterion) 2012 – 2020 – Romanian market total NACE codes
  7. Profit / employee (groups of companies on turnover criterion) 2012 – 2020 – Romanian market total NACE codes
  8. Profit/ company (groups of companies on turnover criterion) 2012 – 2020 – Romanian market total NACE codes
  9. Turnover (Top 10 companies) 2012 – 2020 – Romanian market
  10. Net profit (top 10 companies) 2012 – 2020 – Romanian market
  11. Number of employees (top 10 companies) 2012 – 2020 – Romanian market
  12. Turnover / employee (top 10 companies) 2012 – 2020 – Romanian market
  13. Net profit / employee (top 10 companies) 2012 – 2020 – Romanian market
  14. Financial data of 5 of the top 10 players 2012 – 2020 – Romanian market
PIATA PRODUCTIEI DE MEDICAMENTE ROMANIA 2021
PIATA PRODUCTIEI DE MEDICAMENTE ROMANIA 2021

9.000 lei

Register New Account
Reset Password
Shopping cart